LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lineage Cell Therapeutics Inc (LCTX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, the lack of significant positive catalysts, weak financial performance, and the absence of strong trading signals suggest that it is better to hold off on investing right now. The stock's potential for short-term decline (-4.41% in the next week, -11.34% in the next month) further supports this conclusion.
The stock's MACD is positive and contracting, RSI is neutral at 49.187, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 1.68, R1: 1.852, S1: 1.508, R2: 1.958, S2: 1.402. However, the stock has a 60% chance of declining in the short term based on similar candlestick patterns.
Analyst rating reiterated as Buy with a $9 price target. Roche's progress with OpRegen for dry-AMD and geographic atrophy is a positive long-term catalyst.
No significant news in the recent week. Financial performance shows declining revenue (-2.59% YoY) and significant net losses, despite an improvement in EPS and net income YoY. The stock is expected to decline in the short term based on historical patterns.
In Q3 2025, revenue dropped by -2.59% YoY to $3.68M. Net income improved significantly to -$29.78M (up 881.58% YoY), and EPS increased to -0.13 (up 550.00% YoY). Gross margin slightly increased to 99.86%. Overall, financials show some improvement but remain weak.
H.C. Wainwright reiterated a Buy rating with a $9 price target. The analyst highlighted Roche's progress with OpRegen as a significant long-term catalyst.
